SCHEMBL9883160

SCHEMBL9883160

CCc1ccc2c(O)nccc2c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.34
CYP2D6 P10635 6/20 0.34
CYP2C8 P10632 5/20 0.34
CYP2C19 P33261 5/20 0.34
KCNH2 Q12809 5/20 0.33
CYP2C9 P11712 3/20 0.33
CYP3A4 P08684 3/20 0.33
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
ABCB11 O95342 1/20 0.32
APP P05067 1/20 0.32
CHRM2 P08172 1/20 0.32
HTR1A P08908 1/20 0.32
CHRM1 P11229 1/20 0.32
DRD2 P14416 1/20 0.32
ADRA2C P18825 1/20 0.32
SLC6A2 P23975 1/20 0.32
PTGS2 P35354 1/20 0.32
OPRM1 P35372 1/20 0.32
HTR2B P41595 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13180249 0.80 GABRA1 (0.37) CYP1A2HTR1ADRD2GABRA1GABRB2
SCHEMBL9883264 0.79 GABRA1 (0.39) PDE3BPDE3AGABRA1GABRB2
SCHEMBL15047831 0.77 TLR8 (0.38) CYP3A4PDE3BPDE3AHTR1ACHRM1
SCHEMBL8139929 0.72 CYP19A1 (0.50) CYP1A2CYP2D6CYP2C19CYP3A4HTR2B
SCHEMBL9880932 0.72 CA2 (0.31) CYP2C19CYP2C9ALDH1A1
SCHEMBL9883212 0.70 L3MBTL1 (0.35) CYP1A2CYP2D6CYP2C9CYP3A4HTR1A
SCHEMBL18300750 0.69 MAPT (0.34) CYP1A2CYP3A4APPHTR1ASLC6A2
SCHEMBL5020020 0.67 BUB1 (0.34) PDE3BPDE3AHTR1ADRD2L3MBTL1
SCHEMBL12658946 0.67 CTRC (0.48) HTR1ADRD2GABRA1GABRB2
SCHEMBL9883128 0.67 IMPDH2 (0.56) CYP1A2CYP2D6CYP2C8CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394826-B2 Dual mechanism inhibitors for the treatment of disease AERIE PHARMACEUTICALS, INC. (US) 2013-03-12 US disclosed
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME AERIE PHARMACEUTICALS, INC. 2012-05-31 US disclosed
US-20100280011-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE ALCON INC. (CH) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME SLC6A2, ROCK2, SLC6A4 CYP1A2 1088/4885CYP2D6 1592/4885CYP2C8 1951/4885
US-20100280011-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE RHOA, SLC6A2, ROCK2 CYP1A2 1339/4885CYP2D6 2180/4885CYP2C8 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.